ALFA Finder| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 629.2 | 645.0 | 591.9 |
| Other income | 40.7 | 38.2 | 44.6 |
| Total income | 670.0 | 683.2 | 636.5 |
| Profit before exceptional items & tax | 259.8 | 250.2 | 253.0 |
| Exceptional items | 9.0 | -58.2 | 172.8 |
| Profit before tax | 268.8 | 191.9 | 425.8 |
| Net profit | 199.8 | 141.8 | 330.9 |
| Operating margin | 40.1% | 28.1% | 66.9% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -39.60% |
|---|---|
| Net profit, quarter on quarter | +40.90% |
| Revenue, year on year | +6.30% |
BSE results filing, NSE: PFIZER. Figures extracted from the filing.
Pfizer Ltd: key numbers
- Share price
- ₹3,904.50
- Market cap
- ₹17,862 Cr
- Revenue (annual)
- ₹2,520 Cr
- Net profit (annual)
- ₹722.4 Cr
- P/E (TTM)
- 20.8×Sector 43.8×
- Promoter holding
- 63.92%+0.00% QoQ
- FII holding
- 1.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Pfizer Ltd
All →Pfizer Q2 FY27 Results: Net Profit ₹313.2 Cr, Up 65.7% YoY
Pfizer Limited reported unaudited financial results for the quarter ended September 30, 2026. The company recorded a net profit of Rs. 313.25 Crore on total income of Rs. 774.19 Crore.
- Key figure
- Net profit ₹313.2 Cr · +65.7% YoY
Pfizer Board Meeting Date
Pfizer Limited has scheduled a board meeting for 3 November 2026 to consider unaudited standalone half-yearly results for the period ended September 2026. The trading window closes from 30 September 2026 until 5 November 2026.
Pfizer Other Announcement
Pfizer Ltd has filed its quarterly shareholding pattern as per SEBI regulations. This is a routine compliance disclosure.
Pfizer Legal & Regulatory
Pfizer Limited received a penalty order of Rs. 1.26 Crore from the Income Tax department regarding transfer pricing. The company plans to appeal the order and expects no material financial impact.
- Value
- ₹1.26 Cr
- From
- Deputy / Additional Commissioner of Income tax Transfer Pricing
Pfizer Management Change
Pfizer Limited announced the resignation of Mr. Sharad Goswami, Senior Director – Policy & Public Affairs, effective from the close of business on September 25, 2026.
Pfizer Board Meeting Outcome
Pfizer Board approved discontinuation of Minipress XL effective September 7, 2026. The company will receive ₹131.38 Crore lump-sum payment from Pfizer Inc., USA.
- Value
- ₹131.4 Cr